FDA Approves Tecvayli (teclistamab-cqyv) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Tecvayli, an off-the-shelf, subcutaneous therapy, is an important new medicine for patients with incurable blood cancer who face limited treatment options HORSHAM, Pa., October 25, 2022– The Janssen Pharmaceutical Companies of Johnson...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news